durvalumab + tremelimumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Anaplastic Thyroid Cancer
Conditions
Metastatic Anaplastic Thyroid Cancer
Trial Timeline
Apr 25, 2017 → Jun 3, 2022
NCT ID
NCT03122496About durvalumab + tremelimumab
durvalumab + tremelimumab is a phase 1 stage product being developed by AstraZeneca for Metastatic Anaplastic Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03122496. Target conditions include Metastatic Anaplastic Thyroid Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05345678 | Pre-clinical | Completed |
| NCT07081633 | Phase 2 | Recruiting |
| NCT05883644 | Phase 3 | Active |
| NCT05701488 | Phase 1 | Recruiting |
| NCT05557838 | Phase 3 | Recruiting |
| NCT04430452 | Phase 2 | Recruiting |
| NCT05000710 | Phase 2 | Active |
| NCT04499053 | Phase 2 | Recruiting |
| NCT04395079 | Phase 2 | Active |
| NCT04238637 | Phase 2 | Active |
| NCT03638141 | Phase 2 | Completed |
| NCT03702179 | Phase 2 | Completed |
| NCT03704480 | Phase 2 | Active |
| NCT03601455 | Phase 2 | Active |
| NCT03618134 | Phase 1/2 | Terminated |
| NCT03703297 | Phase 3 | Active |
| NCT03624231 | Phase 2 | Completed |
| NCT03288532 | Phase 3 | Recruiting |
| NCT03283605 | Phase 1/2 | Active |
| NCT03277482 | Phase 1 | Terminated |
Competing Products
20 competing products in Metastatic Anaplastic Thyroid Cancer